Wall Street's major market averages finished mixed as Treasury yields rebounded, rekindling concerns about a deteriorating ...

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Danish drugmaker Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal for the private company ...

The Wegovy maker is betting that a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly ...

Novo Nordisk announced Monday that it is rebranding itself as "Novo" along with updating its corporate culture as it competes ...

Novo Nordisk (NVO) stock rose 4% after announcing an Anthropic AI deal and receiving a European approval recommendation for ...

Novo Nordisk stock gains as Sogroya wins a key EU recommendation for children with idiopathic short stature, bringing broader EU approval a step closer.

The fresh trigger for Novo Nordisk (CPSE:NOVO B) is a CHMP green light for FREHEMGO, a haemophilia A therapy that could add a rare-disease revenue stream alongside its core obesity and diabetes ...

Novo Nordisk has launched a global rebrand that will see the healthcare company increasingly use Novo as its day-to-day name ...

Mike Doustdar, CEO of Novo Nordisk, launches a company rebrand and corporate culture as industry rivals and patent expiries ...

Novo Nordisk (NVO) stock jumped 4% after unveiling an AI collaboration with Anthropic and securing European approval ...

Novo Nordisk A/S ( NVO) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for ...